{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:44:19Z","timestamp":1769021059229,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.pupt.2018.11.002","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T23:24:59Z","timestamp":1541633099000},"page":"25-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study"],"prefix":"10.1016","volume":"54","author":[{"given":"Corrado","family":"Pelaia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4293-4461","authenticated-orcid":false,"given":"Cecilia","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Barbuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Busceti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3492-8830","authenticated-orcid":false,"given":"Mariaimmacolata","family":"Preian\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-7902","authenticated-orcid":false,"given":"Luca","family":"Gallelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Savino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-3037","authenticated-orcid":false,"given":"Alessandro","family":"Vatrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2018.11.002_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2018.11.002_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","volume":"391","author":"Papi","year":"2018","journal-title":"Asthma, Lancet"},{"key":"10.1016\/j.pupt.2018.11.002_bib3","first-page":"879783","article-title":"Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma","author":"Pelaia","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.pupt.2018.11.002_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and non-eosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.11.002_bib5","doi-asserted-by":"crossref","first-page":"L130","DOI":"10.1152\/ajplung.00070.2014","article-title":"Emerging molecular phenotypes of asthma","volume":"308","author":"Ray","year":"2015","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.pupt.2018.11.002_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.pupt.2018.11.002_bib7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1183\/13993003.01824-2014","article-title":"Asthma phenotypes and IgE responses","volume":"47","author":"Froidure","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.11.002_bib8","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.pupt.2018.11.002_bib9","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1172\/JCI84144","article-title":"Current concepts of severe asthma","volume":"126","author":"Ray","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pupt.2018.11.002_bib10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/02770900601031540","article-title":"TENOR Study Group, High prevalence of skin test positivity in severe or difficult-to-treat asthma","volume":"43","author":"Haselkorn","year":"2006","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2018.11.002_bib11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1183\/16000617.00001715","article-title":"Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives","volume":"24","author":"Samitas","year":"2015","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.pupt.2018.11.002_bib12","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and difficult-to-treat asthma in adults","volume":"377","author":"Israel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2018.11.002_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.pupt.2018.11.002_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14712598.2018.1402003","article-title":"Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in children","volume":"18","author":"Pelaia","year":"2018","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.pupt.2018.11.002_bib15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nri1782","article-title":"Integrated signalling pathways for mast cell activation","volume":"6","author":"Gilfillan","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.pupt.2018.11.002_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2172-9-2","article-title":"IgE alone promotes human lung mast cell survival through the autocrine production of IL-6","volume":"9","author":"Cruse","year":"2008","journal-title":"BMC Immunol."},{"key":"10.1016\/j.pupt.2018.11.002_bib17","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1007\/s11033-013-2695-z","article-title":"Different anti-apoptotic effects of normal and asthmatic serum on normal eosinophil apoptosis depending on house dust mite-specific IgE","volume":"40","author":"Kim","year":"2013","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.pupt.2018.11.002_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1067\/mai.2000.108431","article-title":"The relationship between serum IgE and surface levels of Fc\u03b5R on human leukocytes in various diseases: correlation of expression with Fc\u03b5RI on basophils but not on monocytes or eosinophils","volume":"106","author":"Saini","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2018.11.002_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20050811","article-title":"The structure of human CD23 and its interactions with IgE and CD21","volume":"202","author":"Hibbert","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.pupt.2018.11.002_bib20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4049\/jimmunol.157.2.607","article-title":"Peripheral blood dendritic cells express Fc\u03b5RI as a complex composed of Fc\u03b5RI \u03b1- Fc\u03b5RI \u03b3-chains and can use this receptor for IgE-mediated allergen presentation","volume":"157","author":"Maurer","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.pupt.2018.11.002_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1183\/09031936.00203412","article-title":"The plasmacytoid dendritic cell: at the cross-roads in asthma","volume":"43","author":"Lynch","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.11.002_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1389450116666141219122157","article-title":"Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments","volume":"16","author":"Pelaia","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.pupt.2018.11.002_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pupt.2012.04.004","article-title":"The high affinity IgE receptor (Fc\u03b5RI) expression and function in airway smooth muscle","volume":"26","author":"Redhu","year":"2013","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2018.11.002_bib24","doi-asserted-by":"crossref","first-page":"e56015","DOI":"10.1371\/journal.pone.0056015","article-title":"The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodeling","volume":"8","author":"Roth","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pupt.2018.11.002_bib25","doi-asserted-by":"crossref","first-page":"e0136549","DOI":"10.1371\/journal.pone.0136549","article-title":"Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab","volume":"10","author":"Roth","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pupt.2018.11.002_bib26","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nrd3792","article-title":"The potential of biologics for the treatment of asthma","volume":"11","author":"Pelaia","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pupt.2018.11.002_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of asthma: more than a decade of real life effectiveness","author":"Pelaia","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.pupt.2018.11.002_bib28","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2147\/DDDT.S130743","article-title":"Targeted therapy in severe asthma today: focus on immunoglobulin E","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.pupt.2018.11.002_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1753465808100431","article-title":"Omalizumab in the treatment of severe asthma: efficacy and current problems","volume":"2","author":"Pelaia","year":"2008","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.pupt.2018.11.002_bib30","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2018.11.002_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1378\/chest.10-1194","article-title":"Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review","volume":"139","author":"Rodrigo","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2018.11.002_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/all.12815","article-title":"\u2018Real-life\u2019 effectiveness studies of omalizumab in severe patients with severe allergic asthma: systematic review","volume":"71","author":"Abraham","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.pupt.2018.11.002_bib33","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"\u201cReal-life\u201d effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis","volume":"5","author":"Alhossan","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2018.11.002_bib34","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.rmed.2010.04.013","article-title":"Italian real-life experience of omalizumab","volume":"104","author":"Cazzola","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2018.11.002_bib35","doi-asserted-by":"crossref","first-page":"713","DOI":"10.5414\/CP201586","article-title":"Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma","volume":"49","author":"Pelaia","year":"2011","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"10.1016\/j.pupt.2018.11.002_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2018.09.006","article-title":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study","author":"Pelaia","year":"2018","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2018.11.002_bib37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The asthma control test and the asthma control questionnaire for assessing asthma control: systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2018.11.002_bib38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000487482","article-title":"\u201cReal life\u201d efficacy and safety aspects of four-year omalizumab treatment for asthma","volume":"27","author":"Al-Ahmad","year":"2018","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.pupt.2018.11.002_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pupt.2011.11.004","article-title":"Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean \u201creal-life\u201d experience","volume":"25","author":"Tzortzaki","year":"2012","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2018.11.002_bib40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2500\/aap.2015.36.3849","article-title":"Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results","volume":"36","author":"Zazzali","year":"2015","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.pupt.2018.11.002_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.aller.2012.07.006","article-title":"Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal","volume":"42","author":"Vieira","year":"2014","journal-title":"Allergol. Immunopathol."},{"key":"10.1016\/j.pupt.2018.11.002_bib42","author":"National Institute for Health on Care Excellence (NICE)"},{"key":"10.1016\/j.pupt.2018.11.002_bib43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/02770903.2011.561512","article-title":"Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics","volume":"48","author":"Pace","year":"2011","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2018.11.002_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4168\/aair.2017.9.4.368","article-title":"Real life efficacy of omalizumab after 9 years of follow-up","volume":"9","author":"Menzella","year":"2017","journal-title":"Allergy Asthma Immunol. Res."},{"key":"10.1016\/j.pupt.2018.11.002_bib45","doi-asserted-by":"crossref","first-page":"1701782","DOI":"10.1183\/13993003.01782-2017","article-title":"Care pathways for the selection of a biologic in severe asthma","volume":"50","author":"Bousquet","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.11.002_bib46","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000334701","article-title":"Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma","volume":"83","author":"Hoshino","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.pupt.2018.11.002_bib47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/039463201202500217","article-title":"Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients","volume":"25","author":"Riccio","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.pupt.2018.11.002_bib48","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1183\/09031936.00165106","article-title":"Severe exacerbations predict excess lung function decline in asthma","volume":"30","author":"Bai","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.11.002_bib49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2222.2008.03157.x","article-title":"Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype","volume":"39","author":"Dougherty","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.pupt.2018.11.002_bib50","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rmed.2009.09.011","article-title":"Effect of omalizumab on peripheral blood eosinophilia in allergic asthma","volume":"104","author":"Massanari","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2018.11.002_bib51","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2006.02.028","article-title":"Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma","volume":"117","author":"Noga","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2018.11.002_bib52","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effect of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovich","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.11.002_bib53","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.11.002_bib54","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.11.002_bib55","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.pupt.2018.11.002_bib56","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","author":"Casale","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2018.11.002_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.rmed.2017.07.013","article-title":"Long-term \u201creal-life\u201d safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study","volume":"130","author":"Di Bona","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2018.11.002_bib58","doi-asserted-by":"crossref","first-page":"1701782","DOI":"10.1183\/13993003.01782-2017","article-title":"Care pathways for the selection of a biologic in severe asthma","volume":"50","author":"Bousquet","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.11.002_bib59","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/DDDT.S150656","article-title":"Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.pupt.2018.11.002_bib60","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/TCRM.S111862","article-title":"Role of biologics in severe eosinophilic asthma: focus on reslizumab","volume":"12","author":"Pelaia","year":"2016","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.pupt.2018.11.002_bib61","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/DDDT.S155307","article-title":"Benralizumab in the treatment of severe asthma: design, development and potential place in therapy","volume":"12","author":"Pelaia","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.pupt.2018.11.002_bib62","first-page":"4839230","article-title":"Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","author":"Pelaia","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.pupt.2018.11.002_bib63","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1056\/NEJMe1806037","article-title":"New biologics for asthma","volume":"378","author":"Drazen","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553918302451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553918302451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T21:48:26Z","timestamp":1694036906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553918302451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":63,"alternative-id":["S1094553918302451"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2018.11.002","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}